Dr. Copeland on the Role of Chemotherapy in Ovarian Cancer

Video

In Partnership With:

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center—James, discusses the role of chemotherapy in ovarian cancer.

Platinum-based chemotherapy is a standard frontline therapy, says Copeland. However, there is debate as to the optimal delivery method. Intravenous, intraperitoneal, and dose-dense delivery are all potential options for patients.

Additionally, whether to use bevacizumab (Avastin) as up-front therapy or as secondary treatment remains an unanswered question, says Copeland. Moreover, PARP inhibitors have also been added to the frontline space and may complicate treatment decisions, explains Copeland. Ongoing clinical trials may help clarify the relative value of these available options, concludes Copeland.

Related Videos
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD
James Knight, MD
Jason Efstathiou, MD, DPhil